8
Participants
Start Date
August 1, 2020
Primary Completion Date
June 1, 2024
Study Completion Date
July 1, 2024
Tc99m-MAA
Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
Massachusetts General Hospital Cancer Center, Boston
Collaborators (1)
BTG International Inc.
OTHER
Massachusetts General Hospital
OTHER